Table 1.
Promoter methylation of genes in Oral cancer
Gene | Cancer type | Method for methylation analysis | Reference |
---|---|---|---|
TSC2 | Oral squamous cell carcinoma (OSCC) | COBRA | [44] |
CDKN2A, p14ARF | OSCC | MSP | [10] |
MGMT | Head & Neck squamous cell carcinoma (HNSCC) | MSP | [3] |
RASSF1A | Betal-associated oral carcinoma | MSP | [13] |
p16INK4a, p15, MLH1, MGMT, E-CADHERIN | OSCC | Restriction multiplex PCR | [29] |
p16INK4a, RASSF1A, DAPK | Salivary adenoid cystic carcinoma | MSP | [30] |
MGMT | HNSCC | MSP | [21] |
p16INK4a | HNSCC | MSP | [22] |
MGMT, p16INK4a, MLH1 | HNSCC | MSP | [23] |
CNKN2, CDH1, MGMT, DAPK, DBC1, p14, CDKN2B, RARB, RASSF1A, MLH1, p73, DCC, FHIT, SERPINB5 | HNSCC &/or OSCC | MSP, PCR-based restriction assay and/or bisulfite sequencing | [11] |
p16INK4a, CYCLIN A1, RARB, E-CADHERIN, MGMT, STAT1, ATM, MLH1, TIMP3 | SCC of the oral cavity or oropharynx | pryosequencing | [26] |
RASSF2 | OSCC | MSP | [45] |
RECK | OSCC | MSP | [46] |
ATM | HNSCC | MSP | [47] |
p16INK4a, CYTOGLOBIN, CYCLIN A1 | OSCC | pyrosequencing | [35] |
MLH1 | HNSCC | MSP | [15] |
p16INK4a, MGMT, DAPK, E-CADHERIN | Laryngeal and hypopharyngeal cancer | MSP | [24] |
CYTOGLOBIN | Oral or oropharyngeal squamous cell carcinoma | pyrosequencing | [48] |
RIZ1 | Nasopharyngeal carcinoma | MSP | [49] |
CDKN2A | OSCC | [50] | |
p16INK4a, p14ARF, MGMT, RB1, PTEN, p27KIP1 | OSCC | MSP | [51] |
APC | OSCC | MSP | [52] |
CDH1 | HNSCC | MSP | [53] |
p16INK4a, DAPK, E-CADHERIN, RASSF1A | HNSCC | MSP | [54] |
TIMP3, CDH1 | HNSCC | MSP | [55] |
p16INK4a | Oral epithelial dysplasia | MSP | [56] |
RARB, MGMT, RASSF1, E-CADHERIN | Salivary gland carcinoma | pyrosequencing | [57] |
MGMT, p16INK4a | OSCC | MSP | [31] |
RASSF1A, RASSF2A, HIN-1 | OSCC | PCR-denaturing HPLC | [12] |
MLH1, MSH2 | OSCC | MSP | [58] |
RUNX3 | OSCC | MSP | [59] |
LINE-1 | OSCC | COBRALINE-1 | [60] |
SFRP1, SFRP2, SFRP5 | OSCC | MSP | [61] |
miR-137 | OSCC | COBRA and bisulfite sequencing | [62] |